The Acronym Behind Our Wildest AI Dreams and Nightmares
By Émile P. Torres,
Truthdig
| 06. 15. 2023
TESCREAL—pronounced “tess-cree-all.” It’s a strange word that you may have seen pop up over the past few months. The renowned computer scientist Dr. Timnit Gebru frequently mentions the “TESCREAL” ideologies on social media, and for a while the Twitter profile of billionaire venture capitalist Marc Andreessen read: “cyberpunk activist; embracer of variance; TESCREAList.” The Financial Times, Business Insider and VentureBeat have all used or investigated the word. And The Washington Spectator published an article by Dave Troy titled, “Understanding TESCREAL—The Weird Ideologies Behind Silicon Valley’s Rightward Turn.”
My guess is that the acronym will gain more attention as the topic of artificial intelligence becomes more widely discussed, along with questions about the strange beliefs of its most powerful Silicon Valley proponents and critics. But what the heck does “TESCREAL” mean and why does it matter?
I have thought a lot about these questions, as I coined the term in an as-yet unpublished academic paper, co-written with Gebru, tracing the influence of a small constellation of interrelated and overlapping ideologies within the contemporary field of AI. Those ideologies, we believe, are...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...